SVB Leerink reiterated coverage on Abcam with a new price target

3/9/21 5:09:32 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

SVB Leerink reiterated coverage of Abcam with a rating of Outperform and set a new price target of $25.00 from $26.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ABCM

Date	Price Target	Rating	Analyst
6/20/2023	$23.00 → $22.00	Outperform → Sector Perform	RBC Capital Mkts
6/16/2023	$25.00	Neutral → Buy	BofA Securities
12/14/2022	$15.00	Hold	Deutsche Bank